A state-of-the-art facility in Darlington is set to fast-track the development of next-generation RNA therapies thanks to nearly £30 million in government funding
The newly announced UK RNA Biofoundry will play a crucial role in accelerating the development and production of breakthrough treatments for cancer, heart disease, infectious illnesses, and other severe conditions.
Transforming the future of medicine
RNA-based therapies are widely seen as a transformative step forward in medicine. Unlike traditional drugs, RNA therapies are quicker to develop, easier to adapt, and highly targeted.
They work by reprogramming cells, such as immune or tumour cells, to fight disease from within the body, making them a powerful tool for tackling complex conditions like cancer.
The success of mRNA vaccines during the COVID-19 pandemic has already demonstrated the speed and effectiveness of RNA science. Now, with this new facility, the UK aims to build on that momentum and maintain its global lead in this cutting-edge field.
One of the biggest challenges in RNA development has been the ability to manufacture RNA materials at the clinical scale needed for early trials. Many promising ideas never make it past the lab due to high costs and complex production requirements.
The UK RNA Biofoundry will address this gap by serving as a specialised, high-tech manufacturing hub. It will enable scientists and businesses to produce RNA therapies more affordably, quickly, and to the quality standards required for clinical use. The facility will also be capable of pivoting to vaccine production in response to future pandemics, strengthening the UK’s ability to respond to global health emergencies.
Growth and innovation
Located at CPI’s RNA Centre of Excellence in Darlington, the biofoundry will help turn scientific advances into real-world health and economic benefits. It will support the government’s Plan for Change and Life Sciences Sector Plan by fostering innovation, encouraging investment, and building a more resilient healthcare system.
The North East region is expected to benefit significantly from this investment, positioning itself as a centre for advanced biomanufacturing and life sciences innovation. The facility is also a step towards creating more high-value jobs and attracting international partnerships and funding.
Partnerships and national impact
The biofoundry complements other major RNA initiatives already underway in the UK. These include partnerships with leading companies such as BioNTech and Moderna, aiming to bring personalised cancer immunotherapies and other mRNA innovations to NHS patients.
Additional government efforts are also focused on speeding up clinical trial processes, streamlining regulation, and improving access to new treatments through programmes like the NHS Innovator Passport.
This collaborative ecosystem is being supported by organisations including CPI, the Coalition for Epidemic Preparedness Innovations (CEPI), and Wellcome Leap. Together, they aim to ensure that the UK remains a leader in RNA research and production, not only improving patient outcomes but also strengthening the country’s position as a global leader in life sciences.
